Muscle Spasms

Movement Disorder Symptoms Found to Diminish with Alcohol Intake

September 22, 2017

The researchers found that patients showed a significantly reduced number of conditioned eyeblink responses before alcohol administration versus controls.

Mislabeled Muscle Spasm, Parkinson's Drugs Prompt Recall

By July 28, 2017

Accidental dosing with Cyclobenzaprine HCl may potentially lead to life-threatening serotonin syndrome when the drug is taken in combination with selective serotonin reuptake inhibitors.

Research Paper Reviews JFK's Chronic Health Issues

By July 14, 2017

A new review published in the Journal of Neurosurgery: Spine details the health issues that troubled JFK the most, specifically his back. His low-back pain was instigated by a football injury sustained while he was at Harvard in 1937. An orthopedic spine specialist diagnosed him in 1940 with a "very unstable lumbosacral joint".

FDA Expands Dysport Use for Lower Limb Spasticity in Adults

By June 16, 2017

The FDA approval was based on data from a Phase 3, multi-center, prospective, double-blind, randomized, placebo-controlled study in 381 adults treated with Dysport 1000 Units, Dysport 1500 Units or placebo after a stroke or traumatic brain injury.

Risk of Death Up with Long-Term Quinine Exposure

May 15, 2017

Increased risk of death more pronounced among those younger than 50 years regardless of indication

Movement Disorders Examined in Current, Past Stimulant Drug Users

By April 21, 2017

The researchers concluded that stimulant drug use may result in acute stimulant-induced tremor as well as long-term proprioceptive deficits in terms of arm-droop.

Valbenazine for Tardive Dyskinesia

By March 21, 2017

Hauser, Robert A. et al. "KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia"

Genetic Testing Abused by Patient with Factitious Disorder

By March 08, 2017

The patient presented with complaints of increased muscle tone in her back muscles and the right side of her body starting in adolescence.

Cost-Effectiveness of Commonly Used Neck Pain Treatments Compared

November 14, 2016

Findings for SMT home exercise, advice versus rehab, advice or advice alone

FDA to Review Treatment for Levodopa-Induced Dyskinesia

By October 27, 2016

Adamas announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ADS-5102 (amantadine hydrochloride) extended-release capsules, to potentially treat levodopa-induced dyskinesia (LID) in patients with Parkinson's disease (PD).

Propranolol Explored as Possible Tardive Dyskinesia Treatment

By September 14, 2016

A new retrospective study found evidence which suggests that the β-adrenergic blocker propranolol, may be an effective treatment for tardive dyskinesia (TD), for which there are no current approved treatments.

Dysport Approved for Pediatric Lower Limb Spasticity

By August 01, 2016

Ipsen announced that the FDA has approved the supplemental Biologics License Application (sBLA) for Dysport (abobotulinumtoxinA) for injection for the treatment of lower limb spasticity in patients aged ≥2 years. This approval marks Dysport as the first FDA-approved botulinum toxin for this indication.

Lannett Approved for Generic Diazepam Oral Solution

By June 28, 2016

Lannett announced that the Food and Drug Administration (FDA) has approved its Abbreviated New Drug Application (ANDA) for Diazepam Oral Solution, the therapeutic equivalent to Roxane's reference listed product.

New Dosage Strength of Xeomin Launched

By February 09, 2016

Merz Neurosciences announced the launch of Xeomin (incobotulinumtoxinA) in a new 200 Unit single-dose vial.

Botox Gains Lower Limb Spasticity Indication

By January 22, 2016

Allergan announced that the Food and Drug Administration (FDA) has approved Botox (onabotulinumtoxinA) for the treatment of lower limb spasticity in adults to decrease the severity of increased muscle stiffness in ankle and toe muscles.

Xeomin Approved for Adult Upper Limb Spasticity

By December 28, 2015

Merz North America announced that Xeomin (incobotulinumtoxinA) has been approved by the Food and Drug Administration (FDA) for the treatment of upper limb spasticity in adults.

Dysport Gains FDA Approval for Upper Limb Spasticity

By July 17, 2015

Ipsen announced that the Food and Drug Administration (FDA) has approved Dysport (abobotulinumtoxinA) injection for the treatment of upper limb spasticity in adults.

Diazepam Sold Online May Actually Be Antipsychotic, FDA Warns

By July 06, 2015

The Food and Drug Administration (FDA) issued a warning about the potential risk of purchasing counterfeit diazepam online.

Eteplirsen NDA Submission Completed for Duchenne Muscular Dystrophy

By June 30, 2015

Sarepta Therapeutics announced that it has completed a rolling submission of a New Drug Application (NDA) to the Food and Drug Administration (FDA) for eteplirsen.

Botox Label Expanded, Addition of Two Flexor Muscles

By April 20, 2015

The FDA has approved an expansion of the Botox (onabotulinumtoxinA; Actavis) label for the treatment of adults with upper limb spasticity.

FDA: Topical Flurbiprofen Exposure May Be Fatal for Pets

By April 17, 2015

The FDA is warning pet owners, veterinarians, healthcare providers, and pharmacists that pets are at risk of illness and death when exposed to topical pain medications containing flurbiprofen.

Counterfeit Botox Discovered in the U.S.

By April 17, 2015

The FDA is alerting healthcare providers and the public that counterfeit Botox (onabotulinumtoxin A; Allergan) has been found in the United States and may have been distributed to doctors' offices and clinics.

Patients May Need More than Medication to Treat Chronic Back Pain

February 10, 2015

Continuation of multidisciplinary program improves disability, mental health over 30 months

Deflazacort Designated Fast Track Status for Duchenne Muscular Dystrophy

By January 20, 2015

The Food and Drug Administration (FDA) has granted Fast Track designation to deflazacort (Marathon Pharmaceuticals) for the treatment of patients with Duchenne Muscular Dystrophy (DMD).

Dysport sBLA Under Review for Upper Limb Spasticity

December 02, 2014

The Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for Dysport (abobotulinumtoxinA; Ipsen) for the treatment of upper limb spasticity in adults.

Duchenne Muscular Dystrophy Therapy Designated Orphan Drug

November 24, 2014

The Food and Drug Administration (FDA) has granted Orphan Drug designation to CAT-1004 (Catabasis) for the treatment of Duchenne Muscular Dystrophy (DMD).

Neurophysiological Exams Aid in Identifying Back Injury

October 24, 2014

Exams allow for precise indication of level of root injury in patients with lumbosacral disc herniation.

Benzodiazepines Linked to Alzheimer's Risk

September 10, 2014

Benzodiazepine use is associated with an increased risk of Alzheimer's disease, with exposure density correlating with increased strength of association

Eteplirsen NDA Submission Plans for Rare Neuromuscular Disorder

April 21, 2014

Sarepta Therapeutics has announced its plans to submit a New Drug Application (NDA) for eteplirsen for the treatment of Duchenne muscular dystrophy (DMD).

Evidence of Short-Term Opioid Use in Low Back Pain

April 16, 2014

There is evidence of short-term efficacy (moderate for pain and small for function) of opioids for treatment of chronic low back pain (CLBP) compared with placebo; however, the effectiveness and safety of long-term opioid therapy for treatment of CLBP remains unproven.